This was a prospective trial (21 university hospitals) comparing the effectiveness andtime-to-control of 2 treatment protocols during 12 months: (A) a personalized protocolin which the first options were fgSRLs as monotherapy or in combination withpegvisomant, or pegvisomant as monotherapy depending on the short acute octreotide test(sAOT) results, tumor T2 magnetic resonance (MRI) signal or immunostaining forE-cadherin; and (B) a control group with treatment always started by fgSRLs and theother drugs included after demonstrating inadequate control. The gene discussed is CDH17; the disease is neoplasm.